Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in <i>KRAS</i> Wild-Type Patients

<table>Signaling pathways implicated in the lack of response to anti-EGFR therapies. * indicates some receptors or downstream effectors which are responsible for anti-EGFR resistance when they are mutated or overexpressed.</table>

BioMed Research International

fig2

Figure 2

Figure 2: Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in <i>KRAS</i> Wild-Type Patients 

BioMed Research International

Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients

Figure 2